Citations

Mayo Clinic

Clear

597 citation(s) found for "Saá, Paula".

Evidence gaps in the management of sickle cell disease: A summary of needed research
Savage, William, Buchanan, George R., Yawn, Barbara P. , Afenyi‐Annan, Araba, Ballas, Samir K. , Goldsmith, Jonathan C. , James, Allison , John‐Sowah, Joylene, Jordan, Lanetta, Lottenberg, Richard , Murad, M. Hassan , Ortíz, Eduardo , Tanabe, Paula , Lanzkron, Sophie , Hassell, Kathryn Louise , Ware, Russell E. , Murad, M Hassan , James, Andra H

American Journal of Hematology | January 12, 2015 | Volume: 90 | Issue: 4 | Pages: 273-275

10.1002/ajh.23945 | PMID 25639238 Get It

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
Correia, Cristina , Schneider, Paula A., Dai, Haiming , Church, Amy K., Novak, Anne J. , Feldman, Andrew L. , Wu, Xiaosheng , Ding, Husheng, Meng, X. Wei, Macon, William R. , Karp, Judith E. , Gore, Steven D. , Jelinek, Diane F., Nowakowski, Grzegorz S. , Doǧan, Ahmet , Maurer, Matthew J. , Cerhan, James R. , Slager, Susan L. , Habermann, Thomas M. , Kay, Neil E. , Witzig, Thomas E. , Kaufmann, Scott H. , Feldman, Andrew L , Correia, Cristina , Dai, Haiming

Blood | December 1, 2014 | Volume: 125 | Issue: 4 | Pages: 658-667

10.1182/blood-2014-04-571786 | PMID 25452615 Get It

Key Points BCL2 mutations in FL correlate with activation-induced cytidine deaminase expression and frequently alter the amino acid sequence of the protein. Mutations in the BCL2 coding sequence at diagnosis are associated with shortened time to transformation and earlier death due to lymphoma.
Experimental Sleep Restriction Causes Endothelial Dysfunction in Healthy Humans
Calvin, Andrew D. , Covassin, Naima , Kremers, Walter K. , Adachi, Taro, Macedo, Paula , Bukartyk, Jan , Davison, Diane E., Levine, James A. , Singh, Prachi , Wang, Shihan , Albuquerque, Felipe N. , Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Kremers, Walter K

Journal of the American Heart Association | November 25, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001143 | PMID 25424573 Get It

Background Epidemiologic evidence suggests a link between short sleep duration and cardiovascular risk, although the nature of any relationship and mechanisms remain unclear. Short sleep duration has also been linked to an increase in cardiovascular events. Endothelial dysfunction has itself been implicated as a mediator of heightened cardiovascular risk. We sought to determine the effect of 8 days/8 nights of partial sleep restriction on endothelial function in healthy humans. Methods and Results Sixteen healthy volunteers underwent a randomized study of usual sleep versus sleep restriction of two‐thirds normal sleep time for 8 days/8 nights in a hospital‐based clinical research unit. The main outcome was endothelial function measured by flow‐mediated brachial artery vasodilatation ( FMD ). Those randomized to sleep restriction slept 5.1 hours/night during the experimental period compared with 6.9 hours/night in the control group. Sleep restriction was associated with significant impairment in FMD (8.6±4.6% during the initial pre‐randomization acclimation phase versus 5.2±3.4% during the randomized experimental phase, P =0.01) whereas no change was seen in the control group (5.0±3.0 during the acclimation phase versus 6.73±2.9% during the experimental phase, P =0.10) for a between‐groups difference of −4.40% (95% CI −7.00 to −1.81%, P =0.003). No change was seen in non‐flow mediated vasodilatation ( NFMD ) in either group. Conclusion In healthy individuals, moderate sleep restriction causes endothelial dysfunction. Clinical Trial Registration URL : ClinicalTrials.gov. Unique identifier: NCT 01334788.
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia
Ojha, Juhi, Ayres-Silva, Jackline de Paula , Secreto, Charla, Tschumper, Renee C. , Rabe, Kari G. , Dyke, Daniel Van, Braggio, Esteban , Tschumper, Renee, Rabe, Kari, Van Dyke, Daniel, Slager, Susan, Dyke, Daniel L. Van , Slager, Susan L. , Shanafelt, Tait D. , Fonseca, Rafaël , Kay, Neil E. , Chaffee, Kari G. , Braggio, Esteban

Blood | November 6, 2014 | Volume: 125 | Issue: 3 | Pages: 492-498

10.1182/blood-2014-06-580563 | PMID 25377784 Get It

Key Points Deep sequencing identifies a significant reservoir of subclonal mutations affecting key genes in CLL pathogenesis. Convergent evolution of genetic lesions in tumor subclonal populations is recurrently found in CLL.
Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research
O’Bryant, Sid E. , Gupta, Veer Bala , Henriksen, Kim , Jeromin, Andreas, Lista, Simone , Bazenet, Chantal, Soares, Holly , Lovestone, Simon , Hampel, Harald , Montine, Thomas J. , Blennow, Kaj , Foroud, Tatiana, Carrillo, María C. , Graff‐Radford, Neill R. , Laske, Christoph , Breteler, Monique M.B. , Shaw, Leslie M. , Trojanowski, John Q. , Schupf, Nicole , Fagan, Anne M. , Oberoi, Pankaj, Umek, Robert M., Weiner, Michael W. , Grammas, Paula , Posner, Holly, Martins, Ralph N. , groups, STAR-B and BBBIG working, Edwards, Melissa , Rissman, Robert A. , groups, STAR-B and BBBIG working, O'Bryant, Sid

Alzheimer's & Dementia | October 1, 2014 | Volume: 11 | Issue: 5 | Pages: 549-560

10.1016/j.jalz.2014.08.099 | PMID 25282381 Get It

Abstract The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood‐based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross‐validation across cohorts and laboratories.
Validating biomarkers of treatable mechanisms in irritable bowel syndrome
Camilleri, Michael , Shin, Andrea , Busciglio, Irene, Carlson, Paula, Bharucha, Adil E. , Burton, Duane D. , Lamsam, Jesse, Lueke, Alan J., Zinsmeister, A. R., Acosta, Andrés , Donato, Leslie J.

Neurogastroenterology & Motility | September 22, 2014 | Volume: 26 | Issue: 12 | Pages: 1677-1685

10.1111/nmo.12421 | PMID 25244349 Get It

AbstractBackgroundA valid biomarker is ‘an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention’. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS‐diarrhea (IBS‐D) patients, IBS‐constipation (IBS‐C) patients and healthy volunteers (HV).MethodsIn 30 HV, 30 IBS‐C patients and 64 IBS‐D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver‐operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS.Key ResultsThere were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48 h (r = 0.43; p < 0.001) and between fecal BA and IP (r = 0.23; p = 0.015). Individually, fecal BA and CT48 (but not IP) were significant independent predictors for distinguishing HV from IBS. In combination, they discriminated HV from IBS‐D patients (ROCAUC 0.70), HV from IBS‐C patients (ROCAUC 0.73), and IBS‐C patients from IBS‐D patients (ROCAUC 0.86). Colonic transit and fecal BA excretion together discriminate between healthy volunteers and IBS‐C patients or IBS‐D patients, or between the IBS subgroups with 75–90% specificity at 60% sensitivity.Conclusions & InferencesColonic transit and fecal BA individually and together constitute useful biomarkers to identify treatable mechanisms in IBS and to differentiate subgroups of IBS.
Faculty Opinions recommendation of Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Brodsky, Michael C., Grigorian, Paula

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 3, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718538551.793498969 Get It

Case Study of the Redevelopment of Motor Speech Control Following Acquired Brain Damage in Early Childhood
Square, Paula A., Hyman, Ellen, Aronson, Arnold

American Journal of Speech-Language Pathology | July 29, 2014 | Volume: 3 | Issue: 2 | Pages: 67-80

10.1044/1058-0360.0302.67 Get It

This article presents retrospective longitudinal perceptual and acoustic analyses of the recovery of motor speech control in a right-handed 5-year-old male in the 46 weeks following acquired brain damage. The primary lesion site involved the left fronto-parietal cortex. Correlative descriptions of some aspects of linguistic recovery up to 29 months post-onset are also presented. A mute period of 8 days followed a 2-day comatose period. Spontaneous undifferentiated central vowel-like utterances emerged at 11 days post-injury. Intelligible purposeful utterances emerged at 26 weeks post-onset with the motor speech impairment resolving almost completely within the first year post-onset. The motor speech deficit following the mute period was more consistent with the diagnosis of apraxia of speech than dysarthria. Further, the seemingly lateralized damage associated with the communication disorder may indicate that lateralized hemispheric control of motor speech occurs in early childhood. Finally, the redevelopment of motor speech abilities indicates that the young child’s brain is able to reestablish parameters of motor control underlying speech following acquired brain damage.